BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16285040)

  • 21. Non-mammalian models for epigenetic analyses in cancer.
    Schaefer M; Meusburger M; Lyko F
    Hum Mol Genet; 2007 Apr; 16 Spec No 1():R1-6. PubMed ID: 17613542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenome-derived drugs: recent advances and future perspectives.
    Vogiatzi P; Aimola P; Scarano MI; Claudio PP
    Drug News Perspect; 2007 Dec; 20(10):627-33. PubMed ID: 18301797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Hedgehog pathway as a drug target in cancer therapy.
    Lauth M; Toftgård R
    Curr Opin Investig Drugs; 2007 Jun; 8(6):457-61. PubMed ID: 17621875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New targets in oncology drug development.
    Verweij J
    Clin Adv Hematol Oncol; 2005 Oct; 3(10):754-5. PubMed ID: 16258482
    [No Abstract]   [Full Text] [Related]  

  • 25. Modulation of apoptosis signaling for cancer therapy.
    Fulda S; Debatin KM
    Arch Immunol Ther Exp (Warsz); 2006; 54(3):173-5. PubMed ID: 16652217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A radical rethinking of treatment. The aim is to make cancer curable or a manageable chronic disease.
    Hobson K
    US News World Rep; 2008 Nov 3-10; 145(10):48-50, 53. PubMed ID: 18998442
    [No Abstract]   [Full Text] [Related]  

  • 27. Targeting apoptosis as an approach for gastrointestinal cancer therapy.
    Qiao L; Wong BC
    Drug Resist Updat; 2009 Jun; 12(3):55-64. PubMed ID: 19278896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic changes in cancer.
    Grønbaek K; Hother C; Jones PA
    APMIS; 2007 Oct; 115(10):1039-59. PubMed ID: 18042143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Farnesyl transferase inhibitors.
    Li T; Sparano JA
    Cancer Invest; 2008 Aug; 26(7):653-61. PubMed ID: 18665473
    [No Abstract]   [Full Text] [Related]  

  • 30. Signal transduction pathways: signposts to improved therapy for advanced renal cell carcinoma.
    Oestreicher P
    ONS Connect; 2007; 22(8 Suppl):35-6. PubMed ID: 17824556
    [No Abstract]   [Full Text] [Related]  

  • 31. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells.
    Xu W; Neckers L
    Clin Cancer Res; 2007 Mar; 13(6):1625-9. PubMed ID: 17363512
    [No Abstract]   [Full Text] [Related]  

  • 32. Marking off new territory in the search for anticancer compounds: epigenetic mechanisms add complexity and promise to cancer research efforts.
    Nelson B
    Cancer Cytopathol; 2012 Jun; 120(3):143-4. PubMed ID: 22692980
    [No Abstract]   [Full Text] [Related]  

  • 33. [An new generation of antineoplastic agents--targeted therapy in gastrointestinal tumors].
    Lang A; Graeven U
    Zentralbl Chir; 2009 Jun; 134(3):189-92. PubMed ID: 19544236
    [No Abstract]   [Full Text] [Related]  

  • 34. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
    Roukos DH; Tzakos A; Zografos G
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
    [No Abstract]   [Full Text] [Related]  

  • 35. Mechanisms of drug inhibition of signalling molecules.
    Sebolt-Leopold JS; English JM
    Nature; 2006 May; 441(7092):457-62. PubMed ID: 16724058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Signal transduction and its targeting from the cancer molecular genetic platform: applications and perspectives in pulmonary pathology].
    Merlio JP
    Ann Pathol; 2011 Nov; 31(5 Suppl):S40-2. PubMed ID: 22054456
    [No Abstract]   [Full Text] [Related]  

  • 37. Translating epigenetics into an anticancer drug pipeline for solid tumors.
    Roukos DH
    Expert Rev Med Devices; 2011 Jul; 8(4):409-13. PubMed ID: 21728725
    [No Abstract]   [Full Text] [Related]  

  • 38. Biology-driven phase II trials: what is the optimal model for molecular selection?
    Andre F; Delaloge S; Soria JC
    J Clin Oncol; 2011 Apr; 29(10):1236-8. PubMed ID: 21343554
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms.
    Reed JC
    Nat Clin Pract Oncol; 2006 Jul; 3(7):388-98. PubMed ID: 16826219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic biomarkers for human cancer: the time is now.
    Mulero-Navarro S; Esteller M
    Crit Rev Oncol Hematol; 2008 Oct; 68(1):1-11. PubMed ID: 18430583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.